ERBB2 and breast cancer: Targeting CDK4/6 signaling in combination with endocrine therapies significantly improves progression-free survival (PFS) overall survival [1] in patients with advanced estrogen receptor-positive /HER2-negative (ER+/HER2−) breast cancer [2–4] and is now the standard of care for this disease.